Once rapidly fatal, neglected, and orphan diseases without approved therapeutic options, systemic amyloidoses are now highly ...

Sarepta discontinued SRP-5051 development due to safety concerns, despite promising Phase 2 results in dystrophin expression and exon skipping. Persistent hypomagnesemia and declining kidney function ...

Since 1921, when the first therapeutic peptide, insulin, was synthesized, many peptide-related accomplishments have reverberated throughout the industry, with more than 80 peptide drugs being approved ...

RoslinCT, a leading global cell therapy Contract Development and Manufacturing Organization, today announced a strategic partnership with BlueRock Therapeutics, a leader in stem cell therapeutic ...

U.S. Phase III Trial Expands Clinical Investigation of Stem Cell Therapy for Knee Cartilage Defects. CAMBRIDGE, Mass., July 8, 2026 /PRNewswire/ -- MEDIPOST Inc., a biotechnology ...

The status was granted by the FDA's Office of Orphan Products Development and Office of Pediatric Therapeutics.

VERAXA Biotech (NASDAQ: VRXA) announced the initiation of cell line development for its lead BiTAC(R) T-cell engager ...

STEMCELL Technologies and the Centre for Commercialization of Regenerative Medicine (CCRM) today announced a partnership to expand access to high-quality human induced pluripotent stem cell (iPSC) ...

In a development in cancer research, scientists are exploring new therapeutic strategies that move beyond traditional cytotoxic treatments, which have historically targeted uncontrolled cell ...

Since the FDA first approved CAR-T cell therapy in 2017, eight CAR-T drugs have emerged, six of which have been fully approved by the FDA. This groundbreaking cell therapy has brought about a series ...

An innovative gene therapy may help treat a severe and fatal developmental epilepsy syndrome that affects children. Researchers hope that this genetic therapy can also be adapted to other types of ...